Top

Khandan Keyomarsi, Ph.D.

Department of Experimental Radiation Oncology, Division of Radiation Oncology

Present Title & Affiliation

Primary Appointment

Professor, Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

William C. Liedtke, Jr. Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Leader of the Breast Program, Cancer Center Support Grant, MD Anderson Cancer Center, Houston, TX

Founder and Director, TRIUMPH, Translational Research in Multi-Disciplinary Programs for post-doctoral fellows, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1993	Harvard Medical School, Boston, MA, USA, Post-doc, BCMP
1989	University of Southern California, Los Angeles, CA, USA, PHD, Biochemistry
1983	University of California at Santa Barbara, Santa Barbara, CA, USA, BA, Pharmacology

Postgraduate Training

1989-1993

Postdoctoral Fellow, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Experience & Service

Academic Appointments

Director, Training Grant from Cancer Prevention Research Institute of Texas, MD Anderson Cancer Center, Houston, TX, 2017 - Present

Administrative Appointments/Responsibilities

Co-Director of the Breast Cancer Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present

Other Appointments/Responsibilities

Member, Faculty Search Committee Breast Medical Oncology, Houston, TX, 2019 - Present

Member, Faculty Search Committee Experimental Radiation Oncology, Houston, TX, 2019 - Present

Member, Program Affiliation, UTMDACC, Clinical and Translational Oncology, Houston, TX, 2013 - Present

Organizer, First Physician Scientist, Clinical Investigator (PIONEERs) Club for M.D. Anderson Cancer Center, Houston, TX, 2006 - Present

Member, Graduate Program Affiliation, University of Texas, Graduate School of Biomedical Sciences, Cell and Regulatory Biology, Houston, TX, 2006 - Present

Member, Graduate Program Affiliation, University of Texas, Graduate School of Biomedical Sciences, Cancer Biology, Houston, TX, 2000 - Present

Institutional Committee Activities

Member, Post-Doctoral Fellows Task Force Committee, 2019 - Present

Member, Institute for Basic Science Cancer Research, 2009 - 2015

Member, Calabresi Scholar Program Advisory Committee, 2008 - Present

Member, M.S. and PhD Program Steering Committee, 2007 - 2015

Member, Faculty Mentoring Committee, 2007 - 2015

Honors & Awards

2020 - Present	William C. Liedtke, Jr. Chair in Cancer Research
2019 - Present	Distinguished Teaching Professor, MD Anderson Cancer Center
2013 - Present	The University of Texas Kenneth I. Shine Academy of Health Science Education, Academy of Health Science Education Committee

Selected Publications

Peer-Reviewed Articles

Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg 274(2):e150-e159, 2021. e-Pub 2019. PMID: 31436549.
Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi K. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis 10(5):40.doi:10.1038/s41389-021-00324-z, 2021. e-Pub 2021. PMID: 33990543.
Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel) 13(7), 2021. e-Pub 2021. PMID: 33916118.
Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. Am Soc Clin Oncol Educ Book 40:115-126, 2020. PMID: 32421454.
Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. Br J Cancer 122(6):812-822, 2020. e-Pub 2020. PMID: 31942030.
Johnston SJ, Syed BM, Parks RM, Monteiro CJ, Caruso JA, Green AR, Ellis IO, Hunt KK, Karakas C, Keyomarsi K, Cheung KL. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers (Basel) 12(3), 2020. e-Pub 2020. PMID: 32197318.
Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res 25(13):3996-4013, 2019. e-Pub 2019. PMID: 30867218.
Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clin Cancer Res 24(24):6594-6610, 2018. e-Pub 2018. PMID: 30181387.
Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78(19):5481-5491, 2018. e-Pub 2018. PMID: 30194068.
Fu S, Wang Y, Keyomarsi K, Meric-Bernstam , Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs 27(9):1-11, 2018. e-Pub 2018. PMID: 30102076.
Carey JPW, Keyomarsi K. Leveraging MYC as a therapeutic treatment option for TNBC. Oncoscience 5(5-6):137-139, 2018. e-Pub 2018. PMID: 30035166.
Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer. Cancer Res 78(3):742-757, 2018. e-Pub 2017. PMID: 29180466.
Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol 13(1):21-38, 2018. e-Pub 2017. PMID: 29218622.
Franco HL, Nagari A, Malladi VS, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, Dent SYR, Kraus WL. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 28(2):159-170, 2018. e-Pub 2017. PMID: 29273624.
Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, Li J, Franco HL, Nagari A, Malladi VS, Coletta LD, Simper MS, Keyomarsi K, Shen J, Bedford MT, Shi X, Barton MC, Kraus WL, Li W, Dent SYR. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics 19(1):150, 2018. e-Pub 2018. PMID: 29458327.
Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res 23(23):7288-7300, 2017. e-Pub 2017. PMID: 28947566.
Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther 16(9):1751-1764, 2017. e-Pub 2017. PMID: 28619757.
Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res 23(12):2991-3002, 2017. e-Pub 2016. PMID: 27881578.
Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8:15916, 2017. e-Pub 2017. PMID: 28653662.
Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget 8(9):14897-14911, 2017. PMID: 28107181.
Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res 15(1):45-58, 2017. e-Pub 2016. PMID: 27671334.
Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer 8(11):2004-2009, 2017. e-Pub 2017. PMID: 28819400.
Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol 186(7):1900-12, 2016. e-Pub 2016. PMID: 27182644.
JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle 15(12):1579-90, 2016. e-Pub 2016. PMID: 27049344.
Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene 35(19):2428-40, 2016. e-Pub 2015. PMID: 26279297.
Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res 76(8):2406-18, 2016. e-Pub 2016. PMID: 26928812.
Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther 15(4):593-607, 2016. e-Pub 2016. PMID: 26826118.
Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI. PAF-Wnt Signaling-Induced Cell Plasticity Is Required for Maintenance of Breast Cancer Cell Stemness. Nat Commun 7:10633, 2016. e-Pub 2016. PMID: 26843124.
Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33(4):890-4, 2015. e-Pub 2015. PMID: 25947565.
Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The Serine Protease Inhibitor Elafin Maintains Normal Growth Control by Opposing the Mitogenic Effects of Neutrophil Elastase. Oncogene 34(27):3556-67, 2015. e-Pub 2014. PMID: 25195861.
Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 17:87, 2015. e-Pub 2015. PMID: 26108797.
Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer 121(6):806-16, 2015. e-Pub 2014. PMID: 25355050.
Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res 16(6):3417. e-Pub 2014. PMID: 25551582.
Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-Carbinol and its N-Alkoxy Derivatives Preferentially Target ERα-Positive Breast Cancer Cells. Cell Cycle 13(16):2587-99, 2014. PMID: 25486199.
Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5:3459, 2014. e-Pub 2014. PMID: 24619206.
Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1 and pRb dependent manner. Carcinogenesis 34(10):2244-52, 2013. e-Pub 2013. PMID: 23722650.
Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E / CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res 73(13):1-13, 2013. e-Pub 2013. PMID: 23955388.
Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol. e-Pub 2013. PMID: 23517670.
Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res 15(1):R3. e-Pub 2013. PMID: 23320734.
Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Galons H, Joseph B, Meijer L, Hunt KK, Keyomarsi K. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 132(2):575-88, 2012. e-Pub 2011. PMID: 21695458.
Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle 11(7):1468-76, 2012. e-Pub 2012. PMID: 22441703.
Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. (Comment - Loeb KR, ChenX, Too much cleavage of cyclin E promotes breast tumorigenesis, PloS Genet.8(3)1002623 Mar 2012). PLoS Genet 8(3):e1002538, 2012. e-Pub 2012. PMID: 22479189.
Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther 18(7):510-9, 2011. e-Pub 2011. PMID: 21546925.
Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low molecular weight isoform of cyclin E. Cancer Res 71(9):3377-86, 2011. e-Pub 2011. PMID: 21385896.
Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol 27(2):123-31, 2011. e-Pub 2010. PMID: 20853140.
Moghadam SJ, Hanks AM, Keyomarsi K. Breaking the cycle: An insight into the role of ERa in eukaryotic cell cycles. J Carcinog 10:25, 2011. e-Pub 2011. PMID: 22190867.
Caruso JA, Hunt KK, Keyomarsi K. The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer. Cancer Res 70(18):7125-36, 2010. e-Pub 2010. PMID: 20823156.
Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29(27):3896-907, 2010. e-Pub 2010. PMID: 20453888.
Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70(12):5074-84, 2010. e-Pub 2010. PMID: 20530685.
Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res 70(12):5085-95, 2010. e-Pub 2010. PMID: 20530684.
Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle 9(6). e-Pub 2010. PMID: 20237430.
Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 16(4):1179-90, 2010. e-Pub 2010. PMID: 20145171.
Mull BB, Cox J, Bui T, Keyomarsi K. Post-translational modification and stability of low molecular weight cyclin E. Oncogene 28(35):3167-76, 2009. e-Pub 2009. PMID: 19561641.
Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 115(3):651-9, 2009. e-Pub 2008. PMID: 19107593.
Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin B1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15(11):3654-62, 2009. e-Pub 2009. PMID: 19470724.
Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early onset breast cancer. PLoS Med 6(5):e1000068, 2009. e-Pub 2009. PMID: 19536326.
Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8(7):1062-8, 2009. e-Pub 2009. PMID: 19305161.
Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 69(7):2817-25, 2009. e-Pub 2009. PMID: 19318554.
Keyomarsi K. A novel MCM-2 fragment with potential biological function in senescence. Cell Cycle 7(22):3480, 2008. e-Pub 2008. PMID: 19001846.
Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68(19):7966-74, 2008. PMID: 18829554.
Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle 7(15):2434-40, 2008. e-Pub 2008. PMID: 18677105.
Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res 67(23):11272-83, 2007. PMID: 18056453.
von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res 13(20):6032-9, 2007. PMID: 17947465.
Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res 13(16):4800-6, 2007. PMID: 17699858.
Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212-22, 2007. PMID: 17671189.
Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel?. Adv Exp Med Biol 608:52-69, 2007. PMID: 17993232.
Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol 209(3):686-94, 2006. PMID: 17001684.
McGahren-Murray M, Terry NH, Keyomarsi K. The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein. Cancer Res 66(19):9744-53, 2006. PMID: 17018634.
Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via the PI3K Pathway. Cell Cycle 5(15):1654-61, 2006. e-Pub 2006. PMID: 16861913.
Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res 66(2):1040-51, 2006. PMID: 16424040.
Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102(35):12519-24, 2005. e-Pub 2005. PMID: 16116079.
Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280(15):15148-57, 2005. e-Pub 2005. PMID: 15708847.
Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65(3):692-7, 2005. PMID: 15705861.
Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64(9):3198-208, 2004. PMID: 15126360.
Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23(15):2648-57, 2004. PMID: 15007381.
Harwell RM, Mull BB, Porter DC, Keyomarsi K. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem 279(13):12695-705, 2004. e-Pub 2003. PMID: 14701826.
*Efuet EE, Keyomarsi K. Novel mechanism of interaction of statins with the proteasome . Proceedings of the American Association for Cancer Research 44:619, 2003.
Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2(5)(5):461-6, 2003. PMID: 12963845.
Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566-75, 2002. PMID: 12432043.
Blagosklonny MV, Campisi J, Keyomarsi K, Medrano EE. No restriction points in life and science. Cell Cycle 1(2):100-2, 2002. PMID: 12429915.
Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294(5540):173-7, 2001. PMID: 11533444.
Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21(18):6254-69, 2001. PMID: 11509668.
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20(2):147-55, 2001. PMID: 11313944.
Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res 28(23):E101, 2000. PMID: 11095697.
Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst 92(24):1999-2008, 2000. PMID: 11121462.
Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 92(17):1403-13, 2000. PMID: 10974076.
Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Erratum to "Expression of an estrogen receptor alpha variant protein in cell lines and tumors". Mol Cell Endocrinol 166(2):155-69, 2000. PMID: 10996434.
Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol 166(2):156-69, 2000. PMID: 11203301.
Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res 28(10):2108-13, 2000. PMID: 10773079.
Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol 162(1-2):167-80, 2000. PMID: 10854710.
Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60(2):481-9, 2000. PMID: 10667604.
Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 18(41):5691-5702, 1999. PMID: 10577141.
Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 18(40):5691-5702, 1999. PMID: 10523839.
Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 96(14):7797-802, 1999. PMID: 10393901.
Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K. The induction of p21 in breast cancer by modulators of cAMP is through a PKA independent mechanism. Exp. Cell Res 252:211-223, 1999.
Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin induction of CKIs p21 and p27 and mevalonate reversal of lactacystin are both through modulation of the proteasome, independent of HMG-CoA reductase. Proc. Natl. Acad. Sci. USA 96:7797-7802, 1999.
Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17(18):2393-402, 1998. PMID: 9811471.
Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57(4):604-9, 1997. PMID: 9044834.
Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. J Biol Chem 272(3):1842-8, 1997. PMID: 8999870.
Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A 93(26):15215-20, 1996. PMID: 8986790.
Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 24(8):899-905, 1996. PMID: 8869826.
Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 12(12):2535-47, 1996. PMID: 8700512.
Keyomarsi K, Conte D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 11(5):941-50, 1995. PMID: 7675453.
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6(4):387-400, 1995. PMID: 7626805.
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L-H, Zhang P, Dobrowlski S, Bai C, Connell-Crowley L, Swindell E, Fox P, Wei N. Analysis of p21-Cdk Interactions In vitro and In vivo: p21 and p27 can collaborate to inihibit Cdks. Mol. Biol. Cell 6:387-400, 1995.
Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH. Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin. J Med Chem 37(14):2167-74, 1994. PMID: 8035423.
Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54(2):380-5, 1994. PMID: 7903908.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75(4):805-16, 1993. PMID: 8242751.
Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 268(20):15142-9, 1993. PMID: 8325888.
Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90(3):1112-6, 1993. PMID: 8430082.
Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res 52(24):6966-8, 1992. PMID: 1458489.
Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem 267(28):20412-5, 1992. PMID: 1383201.
Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol 118(5):1213-21, 1992. PMID: 1324944.
Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci U S A 89(6):2504-8, 1992. PMID: 1372446.
Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51(13):3602-9, 1991. PMID: 1711413.
Keyomarsi K, Moran RG. Quinazoline folate analogs inhibit the catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate. J Biol Chem 265(31):19163-9, 1990. PMID: 2146271.
Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci U S A 87(22):8950-4, 1990. PMID: 2174168.
Moran RG, Keyomarsi K, Patel R. Biochemical Responses to Treatment with Fluoropyrimidines that Limit Tumor Cell Kill by these Agents. J. Natl. Cancer Inst:71-84, 1988.
Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263(28):14402-9, 1988. PMID: 2971656.
Moran RG, Keyomarsi K, Patel R. Tumor cell responses to inhibition of thymidylate synthase. Adv Exp Med Biol 244:71-83, 1988. PMID: 2977717.
Moran RG, Keyomarsi K. Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monogr(5):159-63, 1987. PMID: 2963229.
Mahnovski V, Cheng MH, Lipsey AI, Keyomarsi K. Drugs in blood donors. Clin Chem 33(1):189, 1987. PMID: 3802478.
Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 46(10):5229-35, 1986. PMID: 2944577.

Invited Articles

Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 15(4):319-26, 2005. PMID: 16043362.
Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59(4):928-42, 2004. PMID: 15234026.
Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 6(5):188-91, 2004. e-Pub 2004. PMID: 15318923.
Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2(4 Suppl 1):S38-47, 2003. PMID: 14508079.
Bedrosian I, Keyomarsi K. Cyclin E and survival in patients with breast cancer. The Amer. J Oncology Rev. 2:97-99, 2003.
Bedrosian I, Keyomarsi K. Synopsis of the NEJM article: Cyclin E in Breast Cancer Patients. Breast Diseases Quarterly 14(3):257-8, 2003.
Keyomarsi K. Synchronization of Mammalian Cells by Lovastatin. Methods in Cell Science 18:1-6, 1996.
Pardee AB, Keyomarsi K. Modification of cell proliferation with inhibitors. Curr Opin Cell Biol 4(2):186-91, 1992. PMID: 1376129.
Fridovich-Keil JL, Hansen LJ, Keyomarsi K, Pardee AB. Progression through the cell cycle: an overview. Am Rev Respir Dis 142(6 Pt 2):S3-6, 1990. PMID: 2252273.

Manuals, Teaching Aids, Other Teaching Publications

McGhren-Murray M, Keyomarsi K. Staurosporine, an essay in the Encyclopedia of Cancer. Springer, 2009.

Editorials

Buchholz TA Keyomarsi K. Regarding Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. Breast Diseases 13, 2002.
Buchholz TA Keyomarsi K. Regarding Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Breast Diseases 13, 2002.
Buchholz TA Keyomarsi K. Regarding Cyclin E immunoexpression in breast ductal carcinoma: pathological correlations and prognostic implications. Breast Diseases 12:304, 2001.

Book Chapters

Alexander A, Keyomarsi K. Exploiting cell cycle pathways in cancer therapy: New (and old) targets and potential strategies. In: Nuclear Signaling Pathways. Springer Science: New York. Human Press, 337-372, 2013.
Lambert L, Lambert D, Keyomarsi K. Understanding the biology of cancer. In: The Biology and Treatment of Cancer. John Wiley & Sons, Inc: Hoboken, NJ/Canada, 103-122, 2009.
Fearmonti R, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. In: Hormone Receptors in Cancer. Springer Science: New York, 125-160, 2009.
Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: Insurmountable chemoresestance or Achilles’ Heel?. In: Breast Cancer Chemosensitivity. Landes Bioscience and Springer Science: Austin, TX and New York, 52-69, 2007.
Keyomarsi K, Pardee AB. Selective Protection of Normal Proliferating Cells Against the Toxic Effects of Chemotherapeutic Agents. In: Prog Cell Cycle Res, 527-532, 2003.
Pardee AB, Keyomarsi K, Dou Q-P. Regulation of the Cell Cycle by Kinases and Cyclins. In: Colony Stimulating Factors: Molecular and Cell Biology, 71-95, 1997.
Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. In: Progress in Cell Cycle Research, 171-191, 1997.
Keyomarsi K, O'Leary N, Pardee AB. Cell Division. In: McGraw Hill Encyclopedia of Science and Technology. 8th. McGraw Hill, 1994.
Moran RG, Keyomarsi K, Colman PD. Preparation of (6-S)5-Formyltetrahydrofolate Labeled at High Specific Activity with 14C and 3H. In: Methods Enzymol, 309-312, Chapter 122, 1986.
Keyomarsi K, Moran RG. Synergistic Interaction Between Folinic Acid and the Flyuoropyrimidines. In: Chemistry and Biology of the Pteridines. Chemistry and Biology of the Pteridines, 691-695, 1986.

Letters to the Editor

Hunt KK and Keyomarsi K. Reply to comment by Dr Mesut Tez on Chagpar A, et al. Clinical Outcome of patients with lymph node negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer, 2005.
Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9: 152, 2003.
Bedrosian I, Tucker SL, Keyomarsi K. Cyclin E in breast Cancer-Reply. N Engl J Med 348: 1064-1064, 2003.
Dou QP, Pardee AB, Keyomarsi K. Cyclin E -- a better prognostic marker for breast cancer than cyclin D?. Nat Med 2: 254, 1996.

Less

Grant & Contract Support

Date:	2023 - 2024
Title:	Strategic Alliance: MDACC/Blueprint CDK2 Sensor Study Project
Funding Source:	UTMDACC-Traction
Role:	Principal Investigator

Date:	2022 - 2029
Title:	Targeting CDK7 in cyclin E overexpressing breast cancer in vitro and in vivo models, Apeiron Therapeutics
Funding Source:	Apeiron Therapeutics
Role:	Principal Investigator
ID:	LS2022-00060718-HB

Date:	2022 - 2029
Title:	The Selective Targeting of CDK4/6 with Ribociclib Provides Survival Benefit in HR+ Breast Cancer
Funding Source:	Novartis
Role:	Principal Investigator
ID:	PLSMTA21FEB44

Date:	2021 - 2024
Title:	Examine the efficacy of CDK2 inhibitor in genetically engineered mouse and human cell line models of cyclin E
Funding Source:	TRACTION/Blueprint
Role:	Principal Investigator

Date:	2021 - 2026
Title:	The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	*Principle Investigator
ID:	RP210028 (Third competitive renewal)

Date:	2021 - 2025
Title:	Examine the efficacy of RP-6175 in genetically engineered mouse and human cell line models of cyclin E
Funding Source:	REPARE THERAPEUTICS
Role:	Principal Investigator

Date:	2020 - 2026
Title:	Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
Funding Source:	NIH/NCI
Role:	Principal Investigator
ID:	R01CA255960

Date:	2020 - 2025
Title:	UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)
Funding Source:	NIH/NCI
Role:	Principal Investigator
ID:	1R25CA240137-01A1

Date:	2018 - 2024
Title:	Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor- Positive Breast Cancer Refractory to Standard Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Leader of the Administrative Core
ID:	RP180712 – MIRA

Date:	2018 - 2024
Title:	Rational Combination Treatment Options to Reverse Resistance in Hormone Receptor-Positive Breast Cancer Refractory to Standard Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-MIRA Leader
ID:	RP180712 – MIRA

Date:	2018 - 2022
Title:	Targeting neutrophil elastase as a novel therapy for metastatic breast cancer,
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-Principal Investigator
ID:	RP180181

Date:	2018 - 2025
Title:	Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator
ID:	1R01CA223772-01

Date:	2017 - 2023
Title:	LIN28 and RNA Uridylation in Breast Cancer: Mouse Models and Molecular Analyses
Funding Source:	NIH/NCI
Role:	Co-Investigator
ID:	1R01CA215186-01A1

Date:	2016 - 2018
Title:	Targeting CDK4 for the treatment of soft tissue sarcoma
Funding Source:	The Alan B, Slifka Foundation
Role:	Principal Investigator

Date:	2016 - 2021
Title:	Palbociclib synergizes with autophagy inhibitors to induce senescence in breast cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator
ID:	RP 170079

Date:	2016 - 2022
Title:	Mechanism of Action and Resistance to CDK4/6 Inhibitors in Breast Cancer
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Mentor of PI
ID:	, BC170615

Date:	2015 - 2019
Title:	Novel Preclinical Therapeutic approached for Triple Negative Breast cancer Targeting the PARP Pathway
Funding Source:	Tesaro Inc
Role:	Principal Investigator

Date:	2015 - 2016
Title:	Targeting the RB-pathway in sarcoma: Utility of CDK4/6 inhibitors
Funding Source:	Sarcoma Foundation of America (SFA)
Role:	Principal Investigator
ID:	Aronsohn Memorial Research Award

Date:	2014 - 2016
Title:	NBCF Prog Mark Ghanian Breast
Funding Source:	UTMDACC
Role:	Principal Investigator
ID:	UTMDACC NBCF Program

Date:	2013 - 2024
Title:	Cancer Center Support (Core) Grant - Breast Cancer Program
Funding Source:	DHHS - NIH-NCI
Role:	Co-Principal Investigator
ID:	5P30 CA016672 36 (PP-RP6)

Date:	2011 - 2017
Title:	Multidisciplinary Subspecialty Pathology Research Fellowship Program
Funding Source:	NIH/NCI
Role:	Multi-Investigator
ID:	1T32CA163185-04

Date:	2011 - 2017
Title:	Lonestar Oncology Network for Epigenetics, Therapy and Research: Breast Cancer Cell Resource Core Facility C:1 Tissue Culture
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Core Leader
ID:	RP110656-CORE 1

Date:	2011 - 2017
Title:	Targeting the cell cycle in triple negative breast cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator
ID:	1 R01 CA152228-01A1

Date:	2010 - 2016
Title:	Proteolytic Processing of Cyclin E in Breast Cancer
Funding Source:	NIH/NCI
Role:	Principal Investigator
ID:	5R01CA087548-14

Date:	2010 - 2021
Title:	The Future of Cancer Research: Training Program for Basic and Translational Scientists
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	*Principal Investigator
ID:	RP140106 (first cycle), RP170064 (competitive renewal)

Date:	2010 - 2015
Title:	Evaluating pharmacological inhibition of neutrophil elastase as an anti-tumor strategy against breast cancer
Funding Source:	Dainippon Sumitomo Pharma Co., Ltd
Role:	Principal Investigator-MDACC
ID:	LS2012-00035908HM

Date:	2010 - 2014
Title:	LMW-E, A Novel Indicator of Letrozole Resistance in Breast Cancer
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Principal Investigator
ID:	KG100876 01

Date:	2010 - 2014
Title:	CDK2 is a Novel Target for Triple Negative Breast Cancer
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Co-Investigator
ID:	1 KG100521 01

Date:	2010 - 2013
Title:	Kimberly Szymanski, Department of Defense Breast Cancer Research Program
Funding Source:	Department of Defense (DOD)
Role:	Mentor of PI
ID:	BC093412

Date:	2010 - 2013
Title:	Natalie Jabbour, Autophagy as a therapeutic target against triple negative breast cancer
Funding Source:	NIH CCTS T32 Fellowship (UT Health Science Center Houston)
Role:	Mentor of GSBS student and PI
ID:	5TL1RR024147

Date:	2010 - 2013
Title:	Joseph A. Caruso, Isaiah J. Fidler Graduate Fellowship in Cancer Metastasis, UT MD Anderson Cancer Center, Graduate Program in Cancer Metastasis Research: From Bench to Bedside
Funding Source:	UT MD Anderson Cancer Center
Role:	Mentor of PI

Date:	2008 - 2011
Title:	MyLinh Duong, Cell cycle deregulation by LMW cyclin E and p53 disrupts mammary acinar morphogenesis. Department of Defense
Funding Source:	Department of Defense (DOD)
Role:	Mentor of PI
ID:	BC083129

Date:	2008 - 2013
Title:	Elizabeth Mittendorf, Cyclin E: Implications for targeted therapy in Her2-overexpressing breast cancer
Funding Source:	NIH/NCI
Role:	Mentor of PI
ID:	K99/R00 CA133244-01

Date:	2008 - 2011
Title:	Nikki Delk, Mechanistic regulation of the tumor specific forms of cyclin E in breast cancer
Funding Source:	NIH/NCI
Role:	Mentor of PI
ID:	1F32CA1282960-01

Date:	2007 - 2010
Title:	Anna Biernacka, Susan G. Komen for the Cure, HER2 and Cyclin E: Novel interaction and opportunities for therapy
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Mentor of PI
ID:	PDF0707621

Date:	2007 - 2009
Title:	Elizabeth Mittendorf, Her2 regulation of low molecular weight cyclin E isoforms in breast cancer, American Association for Cancer Researach-Genentech BioOncology Fellowship for Cancer Research on the Her Family Pathway
Funding Source:	American Association for Cancer Research (AACR)
Role:	Mentor of PI

Date:	2006 - 2011
Title:	PHD training for predoctoral fellows in the area of Clinical and Translational Science
Funding Source:	NIH
Role:	Collaborator
ID:	1TL1RR024147

Date:	2006 - 2009
Title:	Sonia Kamrani, Cell cycle regulation of ER alpha in breast cancer, US Department of Defense
Funding Source:	Department of Defense (DOD)
Role:	Mentor of PI
ID:	W91ZSQ-5323-N746

Date:	2005 - 2011
Title:	Cyclin E as a Novel and Powerful Prognosticator for Breast Cancer
Funding Source:	NIH/NCI
Role:	Project 2 SPORE Principal Investigator
ID:	P50 CA116199

Date:	2005 - 2008
Title:	Tomoya Yokota, Mechanism of elafin downregulation in breast cancer cells
Funding Source:	MDACC Odyssey Fellowship
Role:	Mentor of PI

Date:	2005 - 2008
Title:	Benjamin Mull, Specific reversible cytostatic protection of normal cells against chemotherapeutics in breast cancer therapy, US Department of Defense
Funding Source:	Department of Defense (DOD)
Role:	Mentor of PI
ID:	W23RYX-4322-N635

Date:	2001 - 2010
Title:	Ekem Efuet, Novel Mechanism of interaction of statins with the proteasome: implications in breast cancer
Funding Source:	NIH/NCI
Role:	Mentor of PI
ID:	K01 CA105066

CV information above last modified December 27, 2023

Khandan Keyomarsi, Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Khandan Keyomarsi, Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Book Chapters

Letters to the Editor

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer